PDA

View Full Version : Concert Pharmaceuticals Presents Preclinical Results Supporting Co-Administration Of


News
09-26-2008, 05:10 AM
Concert Pharmaceuticals, Inc. announced today the presentation of data from a preclinical study demonstrating the potential of CTP-347, its novel deuterium-containing serotonin modulator, to avoid the risk of adverse drug-drug interactions when co-administered with tamoxifen, a widely-used breast cancer drug. These data were the subject of a poster presentation at the North American Menopause Society's 2008 Annual Meeting.

More... (http://www.medicalnewstoday.com/articles/123158.php)